Mayo Clinic and United Therapeutics to increase lungs for transplantation in new building dedicated to medical discovery, innovation

August 22, 2019

JACKSONVILLE, Fla. — Mayo Clinic in Florida's new Discovery and Innovation Building opened
on Thursday, Aug. 22. Here, pioneering technology will increase the number of lungs
available for transplant. The 75,000-square-foot building also will house an
innovative Life Sciences Incubator that connects entrepreneurs with
resources to bring medical solutions to market.

Lungs are among the
most fragile and difficult organs to transplant. They are susceptible to injuries and infections, with only about 20% of donor lungs in
the U.S. meeting the standard for transplant. On average, about
300 people die every year waiting for a lung transplant. About 1,400 people are waiting for a
lung transplant, and many more could benefit from a transplant if more viable
lungs were available, according to the United Network for Organ Sharing, the organization that oversees the
nation's organ transplant system.

To address the shortage of suitable lungs, Mayo Clinic and United Therapeutics (NASDAQ: UTHR) announced a collaboration in 2015 that combines the use of United Therapeutics' ex-vivo lung perfusion technology and Mayo Clinic's medical expertise. With ex-vivo lung perfusion (EVLP), donor lungs are flushed and ventilated while being monitored in isolation. This process allows transplant programs to re-evaluate lungs that would otherwise have been discarded.

As part of the
agreement, Mayo Clinic leased land at its Florida location to Lung Biotechnology PBC, a wholly owned
subsidiary of United Therapeutics, to construct the building, and equip and
operate the center. The lungs will be perfused by Lung Bioengineering, a
subsidiary of Lung Biotechnology PBC. Mayo Clinic will provide physician
oversight and work with organ procurement organizations to coordinate the
procurement and delivery of lungs. The lungs will be made available to
patients at Mayo Clinic and other transplant centers. Mayo Clinic and United Therapeutics also will collaborate on the
manufacturing of cell-based therapies for regenerative medicine research, an
innovative area of medicine that could heal damaged tissue and organs.

"We are
excited to work with United Therapeutics in this important and lifesaving collaboration
that ultimately will increase the number of lungs for transplant patients,"
says Kent Thielen, M.D., CEO of Mayo
Clinic in Florida. "Mayo Clinic is firmly committed to using and
developing the latest medical advances and innovations that will have tremendous
benefits not only for our patients, but other patients at institutions throughout
the U.S."

The building includes three surgical suites where donor lungs go through a process called ex vivo lung perfusion. The lungs are then further analyzed and evaluated to determine if they are suitable for transplantation.

The
building includes three ex-vivo lung perfusion surgical suites on the first
floor and collaborative space for conducting cell-based therapy production on
the second floor. The Mayo Clinic Life Sciences Incubator is on the third floor.

"We are honored to work with Mayo Clinic to expand the
supply of transplantable lungs," said Martine Rothblatt, chairman and CEO
of United Therapeutics. "Hundreds of additional transplantable lungs have
been made available through EVLP technology, and we have more than doubled the
number of hours that a lung can be outside of a body before being safely
transplanted. In addition we hope to prevent the need for some lung transplants
and to treat bronchopulmonary dysplasia with new biologic medicines we will
manufacture in the new building."

Mayo Clinic has
one of the nation's largest and most experienced transplant practices,
with locations in Arizona, Florida and Minnesota. More than 200 physicians in
transplant medicine and surgery at these three locations perform about 1,800 organ
transplants per year and have a long track record of excellent outcomes.

Mayo Clinic
established its lung transplant program in
Florida in 2001. Since then, Mayo has performed 648 lung transplants and nine heart-lung transplants. The
three-year survival rate at Mayo Clinic in Florida exceeds the national average
by 9%. The patient survival rate at Mayo is 82% versus 73% nationally.

Mayo Clinic Life Sciences
Incubator

To further accelerate advances in
health care, the Mayo Clinic Life Sciences Incubator will bring together a
community of innovators from across Northeast Florida, providing a hub for
entrepreneurs to explore ideas; develop new health care and life science
products and services; and create new, thriving companies.

The Mayo-led incubator programs will
help:

Inventors and entrepreneurs who wish
to bring new ideas, products or technologies to market

Educators that would like to partner
with the business community

Students that seek experiential
learning opportunities

Companies that want to access new
ideas, products and talent to grow their business portfolios

Economic development agencies that are
eager to attract new business opportunities to the region

Investors searching for new capital
growth opportunities

"The Mayo Clinic Life Sciences
Incubator will provide entrepreneurs in the community with a dedicated facility
and structured programming that links local startups to an array of regional
business, science and investment resources — a partnership of significant and
numerous regional assets," says Charles
Bruce, M.D., chief innovation officer, Mayo Clinic in Florida. "In
turn, a lasting business environment will thrive in the Jacksonville area that
spurs new solutions for patients around the world." Dr. Bruce is medical
director for the incubator.

The Life Sciences Incubator received a
competitive $750,000 federal grant in July from the U.S. Economic Development Administration.
This i6 Challenge grant is designed to fuel high-growth
entrepreneurship and increase access to capital for communities across the U.S.
This grant is awarded to just 26 organizations. Mayo's incubator will use the
funds to collaborate with a dozen regional partners, contributing $12 million to
the economy and creating 120 jobs in the Jacksonville area.

Dr. Bruce, an accomplished innovator
who has helped create seven startup companies and holds 21 patents for medical
inventions, says the award is significant not only for the amount, but also for
the recognition.

"This award is a clear sign of
Mayo Clinic's commitment to the region, our efforts to grow the economy, and
attracting top talent in the life sciences field," Dr. Bruce says. "Mayo
Clinic has earned the confidence and pledged collaboration from the research,
business and economic development communities throughout Northeast Florida, as
well as the backing of local and state government agencies."

Accelerated
growth

Over the past four years, Mayo Clinic in Florida has flourished with major construction and new staff to serve a fast-growing patient population, especially those who require complex medical care. During this time, Mayo Clinic has invested more than $600 million in construction projects and added more than 1,000 new staff members. Two months ago, Mayo Clinic in Florida announced another new major construction project: a $233 million integrated oncology facility that includes proton beam therapy. The 140,000-square-foot facility, which is expected to be completed in late 2023, will be located next to the Mangurian Building.

Mayo Clinic in
Florida has more than 6,000 staff members and contributes nearly $2 billion
annually to the Florida economy.

###

About United Therapeutics United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. The corporation is confident in its future thanks to its fundamental attributes, namely its obsession with quality and innovation, the power of its brands, its entrepreneurial culture and its bioinformatics leadership. The corporation also believes that its determination to be responsible citizens — having a positive impact on patients, the environment and society — will sustain its success in the long term.

Through our wholly owned
subsidiary, Lung Biotechnology PBC, United Therapeutics is focused on addressing
the acute national shortage of transplantable lungs and other organs with a
variety of technologies that either delay the need for such organs or expand
the supply. Lung Biotechnology is the first public benefit corporation
subsidiary of a public biotechnology or pharmaceutical company. [uthr-g]

Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include, among others, United
Therapeutics' and Mayo's expectations regarding the collaboration between
United Therapeutics and Mayo Clinic, and the ability of this collaboration to
result in an increase in the available supply of lungs for transplant. These
forward-looking statements are subject to certain risks and uncertainties, such
as those described in United Therapeutics' periodic reports filed with the
Securities and Exchange Commission (SEC) that could cause actual results to
differ materially from anticipated results. Consequently, such forward-looking
statements are qualified by the cautionary statements, cautionary language and
risk factors set forth in United Therapeutics' periodic reports and documents
filed with the SEC, including the most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. United
Therapeutics claims the protection of the safe harbor contained in the Private
Securities Litigation Reform Act of 1995 for forward-looking statements. This
information is provided as of August 22, 2019, and neither United Therapeutics
nor Mayo Clinic assumes any obligation to update or revise the information
contained in this press release whether as a result of new information, future
events or any other reason.